Favipiravir Therapy in Adults With Mild COVID-19 (Avi-Mild)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT04464408 |
Recruitment Status :
Completed
First Posted : July 9, 2020
Last Update Posted : November 5, 2021
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
COVID-19 | Drug: Favipiravir Drug: Placebo | Phase 2 Phase 3 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 231 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Double (Participant, Investigator) |
Primary Purpose: | Treatment |
Official Title: | A Trial of Favipiravir Therapy in Adults With Mild Coronavirus Disease COVID-19 |
Actual Study Start Date : | July 23, 2020 |
Actual Primary Completion Date : | August 4, 2021 |
Actual Study Completion Date : | August 4, 2021 |

Arm | Intervention/treatment |
---|---|
Experimental: Favipiravir
Favipiravir: 1800 mg (9 tablets) by mouth twice daily for one day, followed by 800mg (4 tablets) twice daily (Maximum days of therapy is 7 days)
|
Drug: Favipiravir
1800 mg twice daily for one day, followed by 800mg (4 tablets) twice daily |
Placebo Comparator: Placebo
9 tablets by mouth twice daily for one day, followed by 4 tablets twice daily (Maximum days of therapy is 7 days).
|
Drug: Placebo
(9 tablets) by mouth twice daily for one day, followed by (4 tablets) twice daily (Maximum days of therapy is 7 days) |
- PCR negative [ Time Frame: 15 days ]Time from randomization to negativity in RT-PCR nucleic acid test for COVID-19 within 15 days of randomization
- Time from randomization to clinical recovery [ Time Frame: 15 days ]The duration from start of treatment (Favipiravir or placebo) to normalization of pyrexia, respiratory symptoms, and relief of cough (or other relevant symptoms at enrollment) that is maintained for at least 72 hours.
- Evaluate symptoms progression [ Time Frame: 28 days ]Evaluate symptoms severity and the disease course progression in both arms till 28 days after starting the medicine.
- Evaluate Faviparivirs effect [ Time Frame: 15 days ]To evaluate Favipiravir's effect on the requirement of the use of antipyretics, analgesics, or antibiotics within 15 days after starting medicine.
- Evaluate Favipiravir's effect [ Time Frame: 28 days ]To evaluate Favipiravir's effect on disease complications within 28 days after starting medicine (hospitalization, ICU admission, or Mechanical ventilation )
- Evaluate the safety of Favipiravir [ Time Frame: 28 days ]Evaluate the safety of investigational drug compared to the control arm within 15 days after starting the medicine. This is assessed by allergic reactions, medication intolerance, liver toxicity, and hyperuricemia in subjects

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 100 Years (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria
Patients must be eligible according to the following criteria for enrollment
- Should be at least 18 years of age
- Male or non-pregnant female (pregnancy testing is not mandatory. If the patient requests or is not sure, the study team will provide it)
- Diagnosed with mild COVID-19* confirmed by positive PCR test for SARS-CoV-2 at the time of recruitment, a result within the last five days
- Patients have to be enrolled within 5 days of disease onset.
Exclusion criteria
Patients meeting any of the following criteria will be excluded from trial enrolment:
- Patients with concomitant documented bacterial pneumonia established through positive sputum cultures
- Patients who are pregnant or breastfeeding
- Known sensitivity/allergy to Favipiravir (If Faviparavir was used for COVID-19 in the patient previously for influenza)
-
Major comorbidities increasing the risk of study drug including
- Hematologic malignancy
- Advanced (stage 4-5) chronic kidney disease or dialysis therapy
- Severe liver damage (Child-Pugh score C, AST> 5 times the upper limit)
- HIV
- Gout/history of Gout or hyperuricemia (two times above the ULN)
(6) Having used Favipiravir or participated in any other interventional drug clinical study within 30 days before the first dose of study drug (i.e., the patient received it for influenza previously) (7) The investigator believes that participating in the trial is not in the best interests of the patient, or the investigator considers unsuitable for enrollment (such as unpredictable risks or subject compliance issues) (8) Clinical prognostic non-survival, palliative care, or in a deep coma and have no response to supportive treatment within three hours of admission.
(9) Hospitalized patients for mild, moderate, or severe COVID-19

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04464408
Saudi Arabia | |
Prince Mohammed Bin Abdul Aziz Hospital - Al Madinah | |
Al Madinah, Saudi Arabia | |
King Fahad Hospital - Madinah | |
Al Madīnah, Saudi Arabia | |
Primary Health Care-Safiyah | |
Al Madīnah, Saudi Arabia | |
King Abdullah Medical City - Makkah | |
Mecca, Saudi Arabia | |
King Abdulaziz Medical City - Riyadh | |
Riyadh, Saudi Arabia | |
Primary Health Care-Al Mansoura | |
Riyadh, Saudi Arabia | |
Primary Health Care-Al Urijah | |
Riyadh, Saudi Arabia |
Principal Investigator: | Mohammad Bosaeed | KAMC-RD, Ministry of National Guard Health Affairs (MNGHA), Saudi Arabia |
Responsible Party: | King Abdullah International Medical Research Center |
ClinicalTrials.gov Identifier: | NCT04464408 |
Other Study ID Numbers: |
RC 20/220/R |
First Posted: | July 9, 2020 Key Record Dates |
Last Update Posted: | November 5, 2021 |
Last Verified: | November 2021 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
Favipiravir COVID19 Mild illness Saudi Arabia |
COVID-19 Respiratory Tract Infections Infections Pneumonia, Viral Pneumonia Virus Diseases Coronavirus Infections Coronaviridae Infections |
Nidovirales Infections RNA Virus Infections Lung Diseases Respiratory Tract Diseases Favipiravir Antiviral Agents Anti-Infective Agents |